GSK and IDEAYA partner in synthetic lethality
The deal gives GSK access to IDEAYA’s MAT2A, Pol Theta, and Werner Helicase programmes
Read More
Tag: IDEAYA
Cancer Researck UK links with Ideaya on PARG inhibitors
Cancer Research UK is partnering with US biotech Ideaya Biosciences to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
